## Abstract ## Background The purpose of the present phase I clinical trial was to evaluate the safety, tolerability, and preliminary efficacy of naked DNA therapy expressing two isoforms of hepatocyte growth factor (pCKโHGFโX7) in critical limb ischemia (CLI) patients. ## Materials and methods
โฆ LIBER โฆ
Naked DNA expressing two isoforms of hepatocyte growth factor induces collateral artery augmentation in a rabbit model of limb ischemia
โ Scribed by Hahn, W; Kim, D-S; Pyun, W-B; Yoo, W-S; Lee, S-D; Won, J-H; Rho, B-S; Park, Z-Y; Kim, J-M; Kim, S
- Book ID
- 109855361
- Publisher
- Nature Publishing Group
- Year
- 2010
- Tongue
- English
- Weight
- 748 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0969-7128
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
A phase I clinical study of naked DNA ex
โ
Yongquan Gu; Jian Zhang; Lianrui Guo; Shijun Cui; Xuefeng Li; Dayou Ding; Jong-M
๐
Article
๐
2011
๐
John Wiley and Sons
๐
English
โ 254 KB
Enhanced cardioprotective effects by coe
โ
Woong Hahn; Wook-Bum Pyun; Dong-Sik Kim; Won-Sun Yoo; Sung-Dong Lee; Jung-Hee Wo
๐
Article
๐
2011
๐
John Wiley and Sons
๐
English
โ 288 KB
## Abstract ## Background The therapeutic potential of pCKโHGFโX7, a naked DNA designed to express two isoforms of hepatocyte growth factor (HGF~723~ and HGF~728~), was studied in the rat ischemic heart disease model. ## Methods First, the kinetics of gene expression was examined by injecting pC